Pfizer India and Cipla on Friday, December 19, announced a strategic partnership under which Cipla will exclusively market and distribute four of Pfizer’s brands in India.As part of the agreement, Cipla will have the sole rights to market, distribute and sell the cough syrups Corex Dx and Corex LS, the non steroidal anti inflammatory drug Dolonex, the proton pump inhibitor Neksium and the oral antibiotic Dalacin C in the Indian market.
Pfizer will continue to manufacture, source and supply these medicines to Cipla for India.
Commenting on the partnership, Meenakshi Nevatia, Country President at Pfizer India, said expanding the reach of Pfizer’s medicines remains a key priority for the company.She added that the collaboration, combining Pfizer’s legacy of innovation and quality with Cipla’s extensive distribution network, is expected to help address the healthcare needs of millions of patients across India.
Pfizer will continue to manufacture, source and supply these medicines to Cipla for India.
Commenting on the partnership, Meenakshi Nevatia, Country President at Pfizer India, said expanding the reach of Pfizer’s medicines remains a key priority for the company.She added that the collaboration, combining Pfizer’s legacy of innovation and quality with Cipla’s extensive distribution network, is expected to help address the healthcare needs of millions of patients across India.
Achin Gupta, Global Chief Operating Officer of Cipla, said the association aligns with Cipla’s focus on strengthening its presence across key therapy areas and improving access to high quality treatments.
He added that Cipla’s distribution capabilities will support wider reach for these trusted therapies, guided by the company’s purpose of ‘Caring for Life’.
Shares of Cipla Ltd. were trading 0.39% higher at ₹1,504.50. The stock is down about 2% so far in 2025.
